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Background: The X-linked recessive disease Duchenne muscular dystrophy (DMD) is caused by mutations in the
gene encoding the protein dystrophin. Despite its large size, dystrophin is a highly stable protein, demonstrating
cooperative unfolding during thermal denaturation as monitored by circular dichroism spectroscopy. In contrast,
internal sequence deletions have been associated with a loss of the cooperative unfolding and cause in vitro protein
aggregation. Several emerging therapy options for DMD utilize internally deleted micro-dystrophins and multi-exon-
skipped dystrophins that produce partially functional proteins, but the stability of such internally truncated proteins has
not been investigated.
Methods: In this study, we analyzed the in vitro stability of human dystrophin constructs skipped around exon 45 or exon
51, several dystrophin gene therapy constructs, as well as human full-length and micro-utrophin. Constructs were
expressed in insect cells using the baculovirus system, purified by affinity chromatography, and analyzed by high-speed
sedimentation, circular dichroism spectroscopy, and differential scanning fluorimetry.
Results: Our results reveal that not all gene therapy constructs display stabilities consistent with full-length human
dystrophin. However, all dystrophins skipped in-frame around exon 45 or exon 51 show stability profiles congruent
with intact human dystrophin. Similar to previous studies of mouse proteins, full-length human utrophin also displays
stability similar to human dystrophin and does not appear to be affected by a large internal deletion.
Conclusions: Our results suggest that the in vitro stability of human dystrophin is less sensitive to smaller deletions at
natural exon boundaries than larger, more complex deletions present in some gene therapy constructs.
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therapyBackground
The X-linked disease Duchenne muscular dystrophy
(DMD) is caused by mutations in the gene encoding the
protein dystrophin [1]. Mutations causing this disease
are variable with 65% of DMD patients harboring dele-
tions which span exons, 5% to 15% having duplications,
and the remaining populations having either point muta-
tions or deep intronic deletions [2]. Becker muscular
dystrophy (BMD) is a milder allelic form of dystrophy
typically caused by in-frame gene deletions that maintain
reading frame but presumably cause disease through di-
minished abundance or functionality [3].* Correspondence: jervasti@umn.edu
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unless otherwise stated.The dystrophin protein is a critical molecular compo-
nent of the dystrophin-glycoprotein complex (DGC) that
functions to maintain skeletal muscle integrity during
contraction [4,5]. Dystrophin provides a structural link
between the sub-sarcolemmal cytoskeleton and the
extracellular matrix through interactions with actin [6,7],
intermediate filaments [8-10], microtubules [11,12], and
the membrane-associated dystroglycan complex [13,14].
The observation that milder BMD patients harbor dele-
tions in the central rod domain suggests that dystrophin
can tolerate such deletions to some degree and that the
central rod domain is less critical to the function of
dystrophin.
Two avenues of therapeutic research have focused on
producing internally truncated, Becker-like dystrophins
in DMD patients. Exon-skipping approaches aim tol. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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using antisense oligonucleotides (ASOs) or phosphoro-
diamidate morpholino oligomers (PMOs), producing an
internally truncated but partially functional protein
[15-17]. Alternatively, adeno-associated viral (AAV) gene
therapy is under active investigation to express miniatur-
ized dystrophin constructs in DMD patients due to the
large size of the dystrophin gene and the limited capacity
of AAV vectors [18-20].
The stability of the corresponding proteins produced
from dystrophin exon skipping or AAV-mediated deliv-
ery of micro-dystrophins is unknown and may be an im-
portant factor to maximize therapeutic efficacy. Previous
in vitro work has demonstrated that the stability of
mouse dystrophin was sensitive to disease-causing mis-
sense mutations and internal deletion [21,22], raising the
question of whether the stabilities of micro-dystrophins
or exon-skipped dystrophins relevant to DMD therapies
might also be compromised. In contrast, the stability of
mouse utrophin, a fetal homologue of dystrophin, was
insensitive to both terminal and internal deletion [22].
Here, we expressed and purified five dystrophins
skipped around exon 45 or 51 with an exon-43-skipped
control, five recombinant dystrophin gene therapy con-
structs, and two utrophin constructs. The selected con-
structs represent the leading therapy approaches that
have been shown to ameliorate the dystrophic phenotype
in mdx mice with transition to clinical trials underway
[19,20,23-28]. In the current study, all constructs were
expressed from human sequences, as opposed to the
mouse constructs used previously [21,22]. Our biophys-
ical analysis revealed that the dystrophin gene therapy
constructs exhibited more variable stabilities in vitro
while exon-skipped dystrophin constructs showed stabil-
ities not different from full-length dystrophin. Consistent
with previous mouse studies, utrophin maintained stabil-
ity despite internal deletion.
Methods
Cloning
A cDNA corresponding to the sequence of full-length
human dystrophin was obtained from the DNASU vector
repository in the pE223 Gateway entry vector. Human
utrophin and micro-utrophin were cloned from HEK293
cells into the pENTR/D-TOPO vector (Invitrogen™,
Waltham, MA, USA) and sequence verified. An eight-
amino-acid FLAG-tag (DYKDDDDK) was added to the
N-terminus of both human dystrophin and utrophin con-
structs for use in purification. All human dystrophin dele-
tion constructs were PCR amplified using primers
designed around adjacent exons, repeats, or domains for
the desired deletion based on reported repeat and domain
boundaries [29]. The PCR products were circularized
using T4 polynucleotide kinase and T4 DNA ligase (NewEngland BioLabs, Ipswich, MA, USA) and sequence veri-
fied. Using the Gateway Recombination system (Life
Technologies, Carlsbad, CA, USA), the deletion con-
structs were recombined into the pDEST8 destination
vector and subsequently transformed into DH10Bac-
competent Escherichia coli and purified according to the
manufacturer’s protocol.
Protein expression and purification
Sf9 insect cells were maintained at 1 × 106 cells/mL in Sf-
900™ II SFM (Life Technologies, Carlsbad, CA, USA).
Purified baculovirus was transfected using Cellfectin® II
(Life Technologies, Carlsbad, CA, USA), and high-titer
viral stocks were generated through successive infections
of Sf9 cells in 3.5-cm plates (P0), 10-cm plates (P1), and
250 mL of 1 × 106 cells/mL suspended cells (P2). Ten mil-
liliters of P2 virus was used to infect 250 mL of 1 × 106
cells/mL and cultured for 72 h post-infection to maximize
protein expression. Infected cells were centrifuged at
1,000 × g for 3 min and re-suspended in phosphate-
buffered saline (PBS) containing a cocktail of protease
inhibitors (100 nM Aprotinin, 10 mg/mL E-64, 10 μM
Leupeptin, 1 mM PMSF, 1 μg/mL Pepstatin). Cells were
lysed by sonication, five bursts of 30 s using a BioLogics
Ultrasonic Homogenizer set at 30% power. The lysate
was centrifuged at 14,000 × g for 10 min at 4°C and the
supernatant applied to an anti-FLAG M2 agarose col-
umn (Sigma Aldrich, St. Louis, MO, USA). The column
was washed with >10 column volumes of PBS and
bound protein eluted with PBS-containing protease
inhibitors and 100 μg/mL FLAG peptide. After dialysis
overnight in 2 L of PBS at pH 7.5, the purified protein
was concentrated using the Amicon Centrifugal Filter
unit (UFC801024), and protein concentration was
determined using A280 and extinction coefficients cal-
culated from the amino acid compositions for each
construct. Concentrated proteins were run on a 3% to
12% sodium dodecyl sulfate (SDS) polyacrylamide gra-
dient gel and run at 150 V for 1 h. Gels were stained
with Coomassie blue stain and visualized using Licor’s
Odyssey® Infrared Imaging System.
Tandem purification of full-length human dystrophin
To optimize the purification of full-length human dystrophin,
a Twin-Strep-tag® (IBA Life Sciences, Göttingen, Germany),
with amino acid sequence SA-WSHPQFEK(GGGS)2
GGSAWSHPQFEK, was cloned onto the C-terminus of
pE223 dystrophin in addition to the N-terminal FLAG-tag.
The dual-tagged dystrophin was then recombined into the
pDEST8 expression vector and expressed in the Sf9 baculo-
virus system as described above. The cell lysate was applied
to a Strep-Tactin ® Superflow ® high-capacity resin (IBA Life
Sciences, Göttingen, Germany), eluted with 100 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, 2 mM desthiobiotin,
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M2 agarose column as described above.
Western blotting
Purification fractions from the tandem purification were
run on a 3% to 12% SDS polyacrylamide gradient gel at
150 V for 1 h. The gel was transferred onto a polyvinyli-
dene difluoride (PVDF) membrane at 100 V for 1 h. The
PVDF membrane was blocked using 5% milk in 1X PBS
and 0.1% Tween and blotted using mouse monoclonal
anti-FLAG M2 (F1804, Sigma Aldrich, St. Louis, MO,
USA) and rabbit polyclonal anti-Strep-tag II (ab76949,
Abcam, Cambridge, UK) antibodies at 1:1,000 dilution.
The blot was visualized using anti-mouse DyLight™ 800
(green channel) and anti-rabbit DyLight™ 680 (red chan-
nel) conjugated antibodies in Licor’s Odyssey® Infrared
Imaging System.
High-speed sedimentation
Each purified protein was diluted to 0.3 mg/mL (for
exon-51-skipped dystrophins) or 0.5 mg/mL (for all
other proteins) with PBS in a final volume of 120 μL,
and 60 μL was immediately aliquoted into 12 μL 6X
Laemmli sample buffer (LSB) to prepare a ‘total’ fraction.
The remaining 60 μL was centrifuged at 100,000 × g for
30 min at 4°C. The supernatant was transferred into
12 μL 6X LSB and the pellet re-suspended in 72 μL of
1X LSB. Triplicate fractions were run on a 3% to 12%
gradient polyacrylamide gel at 150 V for 1 h and stained
with Coomassie blue stain. Gels were scanned using
Licor’s Odyssey® Infrared Imaging System and band
density calculated with Odyssey Software v2.1. Full-
length human dystrophin was used as a control at both
0.3- and 0.5-mg/mL concentrations and did not show
any significant difference in percent aggregation between
the different concentrations (17.6% ± 7.39 and 17.4% ±
7.30, respectively).
Circular dichroism
Each purified protein was centrifuged at 14,000 × g for
10 min at 4°C and the supernatant diluted to 0.5 mg/mL
(for gene therapy and utrophin proteins) or 0.3 mg/mL
(for exon-skipped and full-length dystrophins) using
PBS. Absorption spectra were acquired with a Jasco J-
815 spectropolarimeter, initially at 20°C as controlled by
a Peltier device, from 200- to 260-nm wavelength. Spec-
tra were then acquired at 1°C temperature intervals from
20°C to 90°C and the characteristic ellipticity at alpha-
helical wavelength (θ222) recorded. Molar ellipticity, [θ],
was calculated using the following equation: [θ] = θ /
(10 × c × l) where c is the molar concentration of the
sample (mole/L) and l is the path length in cm. Molar
ellipticity (with units of degrees, centimeter squared per
decimole) was plotted against wavelength for the circulardichroism (CD) spectra. Ellipticity at 222 nm (θ222) was
normalized, plotted against temperature, and fit by re-
gression analysis in Sigma Plot (Systat Software, Inc.,
San Jose, CA, USA) using equations for two-state or
three-state unfolding [30].
Differential scanning fluorimetry
Our method closely followed that described by Niesen
et al. [31]. Briefly, the fluorescent dye SYPRO Orange
(#S6650, Life Technologies™, Carlsbad, CA, USA) was
incubated at a ratio of 1:1,000 (w/w) with 0.5 mg/mL
(or 0.3 mg/mL for exon-skipped proteins) of purified
protein in PBS. The dye/protein solution was aliquoted
into 50-μL technical triplicates, and an emission of
610 nm was measured in a real-time PCR instrument
(iCycler, Bio-Rad, Hercules, CA, USA) as the temperature
was increased from 20°C to 90°C at 1°C temperature inter-
vals. The fluorescence was normalized from 0 to 1, plotted
against temperature, and fit by regression analysis in
Sigma Plot (Systat Software, Inc., San Jose, CA, USA)
using an equation for a two-state unfolding model [30].
Statistical analysis
Data for percentage aggregation and melting temperatures
of single-transition melt curves from CD and differential
scanning fluorimetry (DSF) were analyzed using a one-
way analysis of variance (ANOVA) with Tukey’s post hoc
test in Prism software (GraphPad, San Diego, CA, USA),
all compared to full-length human dystrophin.
Results
Basis for choice of recombinant proteins and gel analysis
The choice of constructs to analyze was based on
current models for exon-skipping and gene therapy in
pre-clinical testing and clinical studies (Figure 1). The
exon-45-skipped and exon-51-skipped dystrophins were
analyzed because they could potentially treat 8% and
13% of DMD patients, respectively [16], and ASO and
morpholino drugs targeting these exons are currently in
clinical trials [32,33]. Therefore, we expressed a subset of
exon-45- and exon-51-skipped human dystrophins:
Δex44-45, Δex45-46, Δex45-51, Δex51-52, and Δex51-63,
as well as Δex43-44, a control deletion that has been pre-
viously speculated to cause decreased stability [34]. While
we initially attempted to generate a larger array of exon-
51-skipped constructs, we analyzed the three (Δex45-51,
Δex51-52, and Δex51-63) that yielded products in the first
stages of cloning.
The gene therapy constructs μH2 human dystrophin
(hDys) and μH3 hDys contain spectrin-like repeats
(SLRs) 1 to 3 and 24 with hinge 2 or hinge 3, respect-
ively. These constructs have been shown to ameliorate
the dystrophic phenotype in mdx mice [27], and μH2
also showed significant expression with muscle
Figure 1 Dystrophin and utrophin constructs analyzed. (A) Diagram of full-length human dystrophin (hDys); NT - N-terminus, CR - cysteine-rich
domain, CT - C-terminus, circles - spectrin-like repeats, diamonds - unstructured ‘hinge’ regions, ABD1/2 - actin binding domains, nNOS BD - neuronal
nitric oxide synthase binding domain, MTBD - microtubule binding domain, DgBD - dystroglycan binding domain, Syn BD - syntrophin binding
domain, DB BD - dystrobrevin binding domain. (B) Diagrams of exon-skipped human dystrophin constructs analyzed. (C) Diagrams of gene
therapy human dystrophins analyzed. (D) Diagrams of full-length human utrophin (hUtr) and a micro-utrophin (μH2 hUtr) analyzed.
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The Δ3990 hDys construct corresponds to the AAV-
delivered micro-dystrophin used in a clinical trial that
reported minimal recombinant dystrophin expression
associated with a strong immune response to dystrophin
[20,37]. Constructs ΔH2-R15/ΔCT hDys and ΔR3-15/
18-23/ΔCT hDys are miniaturized dystrophins that re-
tain SLRs 16 and 17 necessary for sarcolemmal
localization of neuronal nitric oxide synthase (nNOS)
[38,39]. Full-length human utrophin (hUtr) and a micro-
utrophin (μH2 hUtr), homologous to μH2 hDys, corres-
pond to constructs that are under investigation for gene-,
cell-, and protein-based therapies [25,26,28,40].
While gel analysis of the FLAG-affinity-purified re-
combinant proteins revealed a predominant band of the
expected molecular weight for each purified dystrophin
gene therapy and utrophin constructs, full-length and
exon-skipped human dystrophins exhibited a near-stoichiometric contaminating fragment at approximately
230 kDa (Figure 2A, left panel) that was not previously
observed in preparations of full-length mouse dystrophin
[21] and was not present in gene therapy or utrophin
preparations (Figure 2A, middle and right panels). To
identify the contaminating fragment, we generated and
expressed a dual-tagged, full-length human dystrophin
containing a C-terminal Twin-Strep-tag® (IBA Life
Sciences, Göttingen, Germany) in addition to the N-
terminal FLAG-tag. Western blot analysis after tandem
affinity purification of the dually tagged dystrophin
revealed that the near-stoichiometric, approximately
230-kDa contaminating fragment present in the FLAG-
affinity-purified samples was an N-terminal fragment
(green band, Figure 2B) and was mostly likely caused by a
cleavage from a protease in our expression system. The
cleavage event was further confirmed by the presence of
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Figure 2 Gel analysis of purified recombinant proteins. (A) Representative Coomassie-stained gels with 5 μg of exon-skipped dystrophins, gene
therapy dystrophins, and utrophins loaded for comparison. (B) Western blot of purification fractions from tandem purification of dual-tagged
full-length human dystrophin with N-terminal (NT) FLAG-tag (green channel) and C-terminal (CT) Strep-tag (red channel); fractions from Strep
affinity purification and FLAG affinity purifications: load (L), void (V), wash (W), and elute (E). hDys - human dystrophin, hUtr - human utrophin.
McCourt et al. Skeletal Muscle  (2015) 5:13 Page 5 of 10elution fractions of the Strep-tag purification (red band,
Figure 2B). The absence of the contaminating N-terminal
fragment in constructs with deletions preceding repeat 16
combined with its presence in constructs with deletions
after repeat 16 suggests that the proteolytic cleavage site re-
sides within repeat 14 or 15, which would yield the pre-
dicted N-terminal fragment of approximately 230 kDa.
While the tandem purification was successful in identifying
the contaminating fragments and a more purified full-
length dystrophin was recovered (yellow band, Figure 2B),
the resulting yield was not sufficient to support the planned
biochemical or biophysical analyses. Therefore, single








































Figure 3 Analysis of protein aggregation by high-speed sedimentation. Qu
pellet (P) fractions where % aggregation = S/(S + P); full-length human dyst
therapy dystrophins in white bars, and utrophins in lined bars; *P < 0.05, **P <
dystrophin. hUtr - human utrophin.Protein aggregation
High-speed sedimentation is a facile in vitro technique
to quantify aggregation of purified proteins. Full-length
human dystrophin exhibited 17.6% aggregation (Figure 3,
Table 1), which is similar to the 14% aggregation previ-
ously reported for full-length mouse dystrophin [21].
Exon-skipped dystrophin proteins did not show signifi-
cant increases in aggregation relative to full-length
human dystrophin; however, Δex43-44 showed a signifi-
cant decrease in aggregation (gray bars, Figure 3). Four
of the five gene therapy proteins showed a significant in-
crease, with percent aggregation ranging from 31.7% to
44.4% (white bars, Figure 3, Table 1). Interestingly, the

























antification of high-speed sedimentation assay of supernatant (S) and
rophin (hDys) in black bar, exon-skipped dystrophins in gray bars, gene
0.0001 using ANOVA statistical analysis compared to full-length human
Table 1 Biophysical properties of human dystrophin and utrophin constructs
Construct Molecular weight (kDa) CD Tm1 (°C) CD Tm2 (°C) DSF Tm (°C) % Aggregation
hDys 427 48.1 ± 1.17 - 45.7 ± 2.62 17.6 ± 7.11
Δex43-44 414 46.7 ± 0.70 - 44.3 ± 0.35 3.4 ± 0.73*
Δex44-45 413 51.7 ± 1.51 - 48.1 ± 1.54 15.7 ± 2.83
Δex45-46 414 48.4 ± 2.38 - 46.0 ± 2.60 27.9 ± 5.28
Δex45-51 385 47.9 ± 4.07 - 44.6 ± 1.63 10.9 ± 7.00
Δex51-52 414 47.2 ± 0.87 - 43.8 ± 0.31 12.9 ± 6.70
Δex51-63 351 48.6 ± 3.08 - 43.7 ± 1.15 10.4 ± 7.11
μH2 139 47.3 ± 1.25 85.1 ± 4.14 46.0 ± 1.28 44.4 ± 10.10**
μH3 137 49.5 ± 1.78 79.0 ± 2.82 45.8 ± 0.86 31.7 ± 6.72**
Δ3990 154 56.1 ± 1.97** - 50.4 ± 1.91* 11.7 ± 3.97
ΔH2-R15ΔCT 242 53.7 ± 1.51 72.9 ± 4.11 49.8 ± 0.54* 36.2 ± 1.95**
ΔR3-15,18-23 ΔCT 146 45.8 ± 2.96 - 47.3 ± 0.07 36.7 ± 3.96**
hUtr 399 46.2 ± 1.42 - 43.4 ± 0.36 12.5 ± 1.40
μH2 hUtr 138 47.0 ± 1.16 - 42.9 ± 0.25 25.6 ± 3.58
All values are mean values of at least three experiments with standard deviations. CD Tm1 and Tm2: circular dichroism melting temperatures; DSF Tm: differential
scanning fluorimetry melting temperatures. *P < 0.05; **P < 0.0001 using ANOVA statistical analysis compared to full-length human dystrophin (hDys). hUtr –
human utrophin.
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Figure 4 Spectra and melt curves obtained by circular dichroism spectroscopy. (A-C) Circular dichroism absorption spectra from 200 to 260 nm
for exon-skipped dystrophins (A), gene therapy constructs (B), and utrophins (C). Molar ellipticity [θ], with units of degrees centimeter squared
per decimole, was calculated as θ / (10 × c × l) where c is the molar concentration of the sample (mole/L) and l is the path length in cm. (D-F)
CD absorption spectra monitored at 222 nm from 20°C to 90°C for exon-skipped dystrophins (D), gene therapy dystrophins (E), and utrophins
(F). Melt curves were normalized to θ222 from 0 to 1 fraction unfolded and a representative curve plotted. See Table 1 for melting temperatures
(CD Tm1 and Tm2). hDys - human dystrophin, hUtr - human utrophin.
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Figure 5 Melt curves obtained by differential scanning fluorimetry.
Differential scanning fluorimetry (DSF) melt curves for exon-skipped
dystrophins (A), gene therapy dystrophins (B), and utrophins (C).
Fluorescence was monitored at 610 nm from 20°C to 90°C, and
normalized from 0 to 1 fraction unfolded and a representative
curve plotted. See Table 1 for melting temperatures (DSF Tm). hDys
- human dystrophin, hUtr - human utrophin.
McCourt et al. Skeletal Muscle  (2015) 5:13 Page 7 of 10exhibited protein aggregation congruent with full-length
dystrophin. Similar to the exon-skipped dystrophins,
utrophin and micro-utrophin did not vary significantly
from full-length dystrophin aggregation (lined bars,
Figure 3).
Assessment of secondary structure unfolding
To assess secondary structure and protein unfolding,
we analyzed the purified proteins by CD spectroscopy.
All of the constructs exhibited CD spectra characteris-
tic of proteins with high alpha-helical content and
minima at 208 and 222 nm (Figure 4A,B,C). As the
temperature was increased, loss of secondary structure
(or unfolding) was monitored at 222 nm to generate
melt curves (Figure 4D,E,F) with a calculated melting
temperature or temperatures (Table 1). Full-length
human dystrophin exhibited a single-transition melt
curve with a melting temperature of 48.1°C (Figure 4,
Table 1), which is in contrast to the 59.6°C melting
temperature reported for full-length mouse dystrophin
[21]. Upon closer inspection of the melt curves from
the previous report, it is apparent that full-length
mouse dystrophin exhibited an additional melting tran-
sition similar to the dystrophin isoform Dp260 [22], a
property that is absent in CD melt curves of human
dystrophin. Exon-skipped dystrophins exhibited single
transitions all with comparable melting temperatures to
full-length dystrophin (Figure 4D, Table 1). Two of the
gene therapy constructs, Δ3990 and ΔR3-15/18-23/
ΔCT, also displayed a single transition, but Δ3990 had
a significantly higher melting temperature of 56.1°C.
However, the other gene therapy constructs displayed a
second transition with two calculated melting tempera-
tures ranging from 47°C to 85°C (Figure 4E, Table 1).
This indicates that the protein is either not unfolding
cooperatively or is composed of two populations of
folded and unfolded states. Full-length human utrophin
and μH2 hUtr displayed single-transition melt curves with
melting temperatures of 46.2°C and 47°C, respectively
(Figure 4F, Table 1). These values are not significantly dif-
ferent from full-length dystrophin and are consistent with
previously reported melting temperatures for mouse full-
length and micro-mouse utrophins [22].
Assessment of tertiary structure unfolding
DSF utilizes a fluorescent dye that increases its fluores-
cence emission upon binding to hydrophobic moieties in
proteins, which become more exposed and accessible as
a protein unfolds during thermal denaturation [31]. Like
CD, DSF can be used to obtain protein melt curves, but
unlike CD, the signal measured reflects changes in ter-
tiary structure rather than secondary structure. By DSF
analysis, full-length human dystrophin displayed a
melt curve with a single transition at 45.7°C (Figure 5,Table 1). This temperature was lower than that seen in
CD, consistent with the concept that tertiary structure
will be lost before secondary structure. Exon-skipped dys-
trophins displayed single transitions with similar melting
temperatures to full-length dystrophin ranging from 43.7°C
to 48.1°C (Figure 5A, Table 1). In contrast to the CD
data, all of the gene therapy constructs exhibited single
transitions with melting temperatures ranging from 45.8°C
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R15/ΔCT hDys had significantly right-shifted melt curves
from full-length dystrophin with melting temperatures of
50.4°C and 49.8°C, respectively. Full-length and micro-
utrophin both showed a left-shifted melt curve with
melting temperatures of 43.4°C and 42.9°C, respectively,
but like exon-skipped dystrophins, these values are
not significantly different from full-length dystrophin
(Figure 5C, Table 1).
Discussion
In this study, we have analyzed the biophysical proper-
ties of several therapeutically relevant, internally trun-
cated dystrophins and utrophins. Therapies that produce
internally deleted dystrophins are based on observations
that patients with the milder BMD can harbor large de-
letions in the central rod domain. In addition to confer-
ring elasticity or flexibility to dystrophin [5,41,42], it is
known that the central rod domain encodes a second
actin binding domain [6,43,44], as well as domains for
localizing nNOS to the sarcolemma [38,39], for in vitro
binding to phospholipids [45,46], intermediate filaments
[9], and microtubules [11,12].
The biophysical properties of individual and tandem
repeats of the rod domain have been extensively investi-
gated, and these findings demonstrate a wide range of
stabilities [45-48], whereas full-length dystrophin has re-
markable cooperative stability [21]. Additionally, there is
evidence that certain internal deletions of the central
rod domain are associated with increased protein aggre-
gation and instability [22]. Together, these studies sug-
gest that the stability of individual or tandem repeat
fragments does not necessarily reflect that of larger frag-
ments or full-length dystrophin proteins and that pro-
tein stability of individual regions within dystrophin is
context dependent.
Several groups have investigated the biophysical conse-
quences of exon-skipping on dystrophin fragments
within the central rod domain, particularly those span-
ning exons 43 to 51 [34,49-51]. For constructs skipping
exon 51, they concluded that some protein fragments
are more stable than others. Our results, however, sug-
gest that for dystrophins skipped around exon 51, there
is little measureable change in stability in vitro between
exon-skipped proteins and full-length human dys-
trophin. This conclusion is consistent with the conclu-
sions of a recent report that assessed the structural
differences and stability profiles of human dystrophin
fragments with deletions around exon 51 [52]. They
found that while there were marked structural differ-
ences between the different deletion fragments, the sta-
bility was not significantly affected.
For the common, out-of-frame deletion of exon 45
(Δ45) in patients, exon-skipping therapies are beingdesigned to either delete exon 44 (Δex44-45) or exon 46
(Δex45-46) to correct the reading frame. Based on an-
other recent report, it was speculated that the Δex45-46
dystrophin protein might be highly unstable because this
in-frame deletion is associated with the more severe
DMD phenotype in patients [53], and therefore, a
Δex44-45-skipping strategy would be more beneficial.
However, based on our in vitro data, there does not ap-
pear to be any significant difference in stability between
Δex44-45 and Δex45-46 and full-length dystrophin pro-
teins. These different conclusions from the clinical and
in vitro studies indicate that the source of pathogenesis
from the exon 45 to 46 deletion may not depend on the
stability of the resulting protein but, perhaps, is caused
by a regulatory or functional perturbation.
Interestingly, all of the exon-skipped dystrophins eval-
uated in our study displayed in vitro stabilities congruent
with full-length dystrophin, including the Δex43-44 pro-
tein that exhibited decreased stability when previously
evaluated in the context of a smaller recombinant fragment
encompassing SLRs 16 to 18 [34]. Because dystrophy-
causing missense mutations also cause less dramatic
instability in full-length dystrophin compared to small frag-
ments [21,54], it seems possible that long-range and
cooperative intra-protein communication may serve to buf-
fer dystrophin against the destabilizing effects of sequence
changes and deletions.
We also expressed internally deleted human micro-
dystrophins that are currently under investigation for
gene therapy. We showed that several of these con-
structs have significantly different stability compared to
the full-length human dystrophin protein. Both micro-
dystrophins μH2 hDys and μH3 hDys displayed in-
creased aggregation and additional melting transitions
upon secondary structure unfolding. One of the sarco-
lemmal nNOS-localizing constructs, ΔH2-R15/ΔCT
hDys, displayed similar behavior. Interestingly, the more
truncated nNOS-localizing construct, ΔR3-15/18-23/
ΔCT, exhibited a single melting transition similar to full-
length dystrophin but also increased aggregation. These
data suggest that the in vitro stability of dystrophin gene
therapy constructs may be dependent on the stability of
the non-native junction created by the internal deletion.
The Δ3990 hDys construct was the only gene therapy
construct that exhibited wild-type aggregation, and it
displayed significantly increased melting temperatures
for both CD and DSF, suggesting that the Δ3990 protein
is more stable than full-length dystrophin. However, a
small clinical trial for AAV-mediated delivery of the
Δ3990 was not successful [37].
Utrophin-replacement therapies are also currently
under investigation; therefore, we analyzed the stability
of full-length human utrophin and a micro-utrophin.
Our previous study demonstrated that mouse utrophin
McCourt et al. Skeletal Muscle  (2015) 5:13 Page 9 of 10is a highly stable protein that does not appear to be sen-
sitive to terminal truncation or internal deletion [22].
Consistent with these results, our data showed that both
full-length and micro-utrophin have similar protein
aggregation to dystrophin and maintain melting temper-
atures that are not significantly different from full-length
human dystrophin. Investigation of utrophin as a dys-
trophin substitute therapy for DMD [25,26,28,40] is
based on its ability to rescue most phenotypes of the
mdx mouse when transgenically overexpressed [55] and
also the positive correlation between increased utrophin
expression with improved prognosis in a small cohort of
DMD patients [56]. Utrophin maintains some functional
properties of dystrophin, such as forming an analogous
utrophin-glycoprotein complex [57] and binding actin
filaments [58], but lacks the ability to localize nNOS to
the sarcolemma [39,59] and organize the sub-sarcolemmal
microtubule lattice [12]. While utrophin cannot com-
pletely substitute for dystrophin in terms of protein-
protein interactions, our results suggest that utrophin and
micro-utrophin proteins are appealing as therapeutic
targets in terms of protein stability, especially when com-
pared to dystrophin gene therapy proteins.
While the recombinant dystrophin and utrophin pro-
teins used in this study were expressed in a eukaryotic cel-
lular environment, their purification and characterization
in more simple buffers leaves open the possibility that they
exhibit unfolding and aggregation properties in vitro that
are different from how they behave in the complex envir-
onment of a mammalian muscle cell. It will therefore be
important to develop both cell- and tissue-based model
systems to better understand how deletions in dystrophins
and utrophins affect stability in vivo.Conclusions
Our in vitro analysis of the biophysical consequences of
internal deletion on dystrophin and utrophin suggests
that dystrophin stability is context-dependent: relatively
unaffected by small deletions at natural exon boundaries
but sensitive to larger and more complex rearrange-
ments from deletions present in gene therapy constructs.
In contrast, utrophin maintains uniform stability despite
large internal deletion. Moreover, our results also high-
light the need to better understand how differences in
protein stability in vitro translate to therapeutic efficacy
in vivo.
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